Aug 30, 2024

Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:

• Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder...

Aug 30, 2024

Featuring an interview with Dr Michiel van der Heijden, including the following topics:

• Underlying biological mechanisms of the bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition (0:00)
• Treatment patterns and survival outcomes for patients admitted to the intensive care...

Jul 18, 2024

Featuring perspectives from Dr Rana R McKay and Prof Thomas Powles, including the following topics:

• Introduction (0:00)
• Management of Metastatic Clear Cell Renal Cell Carcinoma (RCC) — Prof Powles (12:39)
• Treatment Approaches for Nonmetastatic RCC; Optimal Care of Patients with Non-Clear Cell RCC — Dr McKay (49:27)

Jun 18, 2024

Featuring perspectives from Dr Petros Grivas, including the following topics:

• Collaboration between urologists and medical oncologists for the management of urothelial bladder cancer (UBC) (0:00)
• Evolution of treatment modalities for non-muscle-invasive bladder cancer (NMIBC) (11:16)
• Perspective on recurrence...

Jun 7, 2024

Featuring perspectives from Dr Matthew D Galsky and Dr Ashish M Kamat, including the following topics:

• Introduction: Urologist for Life (0:00)
• Non-Muscle-Invasive Urothelial Bladder Cancer (UBC) Update (9:54)
• Enfortumab Vedotin/Pembrolizumab Now and in the Future (30:21)
• HER2-Positive UBC (37:33)
• Future Directions —...